A Study of AK112 in Combination With VG2025 in Colorectal Cancer With Liver Metastases
Trial statusNot yet recruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorAkeso
About this trial
An open-label, multicenter, phase Ib/II study of AK112 in combination with VG2025 for advanced colorectal cancer with liver metastases.
Eligibility criteria
Qualifiers
Signed informed consent
Age≥18 years and ≤ 75 years
Histologically or cytologically confirmed unresectable colorectal cancer with liver metastases; adenocarcinoma type
Disease progression after first- or second-line standard therapy
Disqualifiers
Histologically or cytologically confirmed non-adenocarcinoma or mixed-type tumors with adenocarcinoma component ≤70%
Known dMMR or MSI-H
Known RAS or BRAF mutations
Participation in another clinical trial
Trial design
Treatments tested in this trial
- VG2025
- AK112
Treatment groups
72 Participants
are divided into 2 treatment groupsSponsors and collaborators
Akeso
Lead sponsor
Shanghai Virogin Biotech Co., Ltd.
Collaborator
Source ClinicalTrials.gov